Olanzapine-induced acute rhabdomyolysis - A case report

被引:17
作者
Baumgart, U
Schmid, R
Spiessl, H
机构
[1] Univ Regensburg, Dept Neurol, D-8400 Regensburg, Germany
[2] Univ Regensburg, Dept Psychiat & Psychotherapy, D-8400 Regensburg, Germany
关键词
D O I
10.1055/s-2005-837770
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A 29-year-old white man with first diagnosis of acute paranoid schizophrenia received for the first time a neuroleptic medication. On admission, creatine phosphokinase (CK) was within normal range (86 U/l). Two days after initiation of treatment with olanzapine (10 mg per day), the patient complaint about mild muscle jerks, and elevated serum CK (949 U/l) was found. One day later, serum CK raised within hours from 9250 U/l up to 34 503 U/l peak concentration. There was no clinical evidence of a neuroleptic malignant syndrome (NMS) or other muscle diseases. After stopping drug treatment and forced diuresis serum CK returned to normal levels within two weeks without acute renal failure. The case report points to necessity of monitoring serum CK during olanzapine treatment when mild muscular symptoms occur.
引用
收藏
页码:36 / 37
页数:2
相关论文
共 16 条
  • [1] The other medical causes of rhabdomyolysis
    Allison, RC
    Bedsole, L
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2003, 326 (02) : 79 - 88
  • [2] Beasley CM, 1997, J CLIN PSYCHIAT, V58, P13
  • [3] Olanzapine - An updated review of its use in the management of schizophrenia
    Bhana, N
    Foster, RH
    Olney, R
    Plosker, GL
    [J]. DRUGS, 2001, 61 (01) : 111 - 161
  • [4] Uncommon side effects associated with olanzapine - A case report
    Farooque, R
    [J]. PHARMACOPSYCHIATRY, 2003, 36 (02) : 83 - 83
  • [5] Neuroleptic malignant syndrome associated with olanzapine
    Johnson, V
    Bruxner, G
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1998, 32 (06) : 884 - 886
  • [6] Life threatening neuroleptic malignant syndrome due to olanzapine
    Kopf, A
    Köster, J
    Schulz, A
    Krömker, H
    Becker, T
    [J]. PSYCHIATRISCHE PRAXIS, 2003, 30 (05) : 279 - 282
  • [7] Löffler W, 2003, PHARMACOPSYCHIATRY, V36, P105
  • [8] Marked elevation of serum creatine kinase associated with olanzapine therapy
    Marcus, EL
    Vass, A
    Zislin, J
    [J]. ANNALS OF PHARMACOTHERAPY, 1999, 33 (06) : 697 - 700
  • [9] Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment
    Meltzer, HY
    Cola, PA
    Parsa, M
    [J]. NEUROPSYCHOPHARMACOLOGY, 1996, 15 (04) : 395 - 405
  • [10] SKELETAL-MUSCLE NECROSIS FOLLOWING MEMBRANE-ACTIVE DRUGS PLUS SEROTONIN
    MELTZER, HY
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1976, 28 (01) : 41 - 56